Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

ClinicalTrials.gov ID: NCT04428788

Public ClinicalTrials.gov record NCT04428788. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-resistant Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.

Study identification

NCT ID: NCT04428788
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Celgene; Industry
Enrollment: 131 participants

Conditions and interventions

Conditions

Prostatic Neoplasms

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 22, 2020 (Actual)
Primary completion: Oct 28, 2025 (Actual)
Completion: Oct 28, 2025 (Actual)
Last update posted: Dec 22, 2025

2020 – 2025

United States locations

U.S. sites: 19
U.S. states: 13
U.S. cities: 17

Facility	City	State	ZIP	Site status
Local Institution - 116	Stanford	California	94305-5826	—
Local Institution - 122	Washington D.C.	District of Columbia	20010	—
Local Institution - 103	Sarasota	Florida	34232	—
Local Institution - 121	Thomasville	Georgia	31792	—
Local Institution - 108	Baltimore	Maryland	21287	—
Local Institution - 104	Boston	Massachusetts	02215	—
Local Institution - 117	Ann Arbor	Michigan	48109	—
Local Institution - 102	Grand Rapids	Michigan	49546	—
Local Institution - 112	New York	New York	10029	—
Local Institution - 109	New York	New York	10032	—
Local Institution - 105	New York	New York	10065	—
Local Institution - 106	Durham	North Carolina	27710	—
Local Institution - 120	Allentown	Pennsylvania	18103	—
Local Institution - 113	Philadelphia	Pennsylvania	19104	—
Local Institution - 107	Dallas	Texas	75235	—
Local Institution - 119	Houston	Texas	77030	—
Local Institution - 101	San Antonio	Texas	78229	—
Local Institution - 115	Seattle	Washington	98109	—
Local Institution - 111	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04428788, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 22, 2025 · Synced Oct 20, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04428788 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →